Summary
For Year 2026-27, EVOQ Remedies reports the following shareholding: Total Promoters at 11.21%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 88.79%. This breakdown provides a quick snapshot of ownership distribution for EVOQ Remedies in 2026-27.
EVOQ Remedies FAQs
As of 04-2026, the promoter shareholding in EVOQ Remedies stands at 11.21% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of EVOQ Remedies is 0% and 0% respectively.
The retail shareholding of the EVOQ Remedies is 88.79%.
Changes in shareholding patterns of EVOQ Remedies can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of EVOQ Remedies are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
